🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Guardion Health Sciences adjourns meeting for plan vote

EditorBrando Bricchi
Published 05/23/2024, 03:22 PM
GHSI
-

HOUSTON - Guardion Health Sciences, Inc. (NASDAQ:GHSI), a clinical nutrition company, has announced the approval of the sale of its Viactiv business by its stockholders at a special meeting held today. The company has subsequently adjourned the meeting to May 31, 2024, to allow additional time for management to solicit proxies in support of its Plan of Liquidation and Dissolution.

The adjournment aims to secure approval from a majority of the company's common stock, which is necessary for the plan's adoption. The plan, detailed in the definitive proxy statement filed on April 8, 2024, includes the flexibility for the board to abandon the dissolution if an alternative proposal emerges that would benefit the stockholders more favorably.

Chairman of the Board, Robert N. Weingarten (NYSE:WRI), expressed gratitude for the stockholders' overwhelming support for the liquidation and dissolution plan and remains hopeful that the extended time will encourage further affirmative votes.

The sale of Viactiv to Doctor’s Best Inc., a subsidiary of Kingdomway USA Corp., is part of a broader strategic review by Guardion's Board of Directors. The transaction, agreed upon on January 30, 2024, for $17,200,000, is expected to close by June 30, 2024, pending customary closing conditions.

If the liquidation and dissolution proposal is approved and the Viactiv sale is completed, stockholders could receive liquidating cash distributions between $9.00 and $11.00 per share. However, if the plan is not approved or the transaction fails to close, the company warns of a substantial risk to the value of its shares.

The company's Board of Directors unanimously recommends stockholders vote in favor of the dissolution proposal. They caution that failure to approve the plan could hinder the company’s ability to quickly distribute cash from the sale and maintain its NASDAQ listing.

This news is based on a press release statement. Guardion Health Sciences continues to seek the support of its stockholders for the proposed liquidation and dissolution, with the aim of delivering the best outcome for its stockholders.

InvestingPro Insights

As Guardion Health Sciences, Inc. (NASDAQ:GHSI) navigates through its strategic decisions, the latest data and insights from InvestingPro can provide stockholders with additional context for their investment considerations. Guardion's market capitalization stands at a modest $11.84 million, reflecting the size and scale of the company within the clinical nutrition space. Despite the challenges, the company has managed to maintain a gross profit margin of 43.43% over the last twelve months as of Q1 2024, indicating its ability to retain a significant portion of revenue after accounting for the cost of goods sold.

However, it is important for investors to note that Guardion has been operating at a loss, with an operating income margin of -29.73% during the same period. Moreover, the company's P/E ratio is currently negative at -2.53, suggesting that earnings are negative and the company is not profitable at this time. This aligns with one of the InvestingPro Tips, which indicates that analysts do not anticipate the company will be profitable this year. Additionally, Guardion does not pay a dividend to shareholders, which may influence the investment decisions of those seeking regular income.

Another key insight for stockholders is the company's price performance. Guardion has experienced a large price uptick over the last six months, with a 49.67% return, and year-to-date, the total return has been an impressive 70.41%. This could signal a potential turnaround or investor optimism about the company's future prospects, despite the historical price performance being less favorable.

For investors looking for more in-depth analysis, there are additional InvestingPro Tips available on the platform, which also highlight that Guardion holds more cash than debt on its balance sheet and that its liquid assets exceed short-term obligations. This information could be particularly relevant considering the company's current liquidation and dissolution plans. To explore these tips and more, stockholders can visit InvestingPro and take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. In total, there are 11 additional tips listed on InvestingPro that could further guide investment decisions regarding Guardion Health Sciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.